This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: April 17, 2009
Last updated: November 12, 2012
Last verified: November 2012
The primary objective of this study is to assess the safety and efficacy of different dose regimens of ILV-094 compared with placebo, administered subcutaneously to subjects with active rheumatoid arthritis who are taking methotrexate.

Condition Intervention Phase
Rheumatoid Arthritis Other: Placebo Drug: ILV-094 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Parallel, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of ILV-094 Administered Subcutaneously To Subjects With Active Rheumatoid Arthritis On A Stable Background Of Methotrexate

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • American College of Rheumatology (ACR) 20% improvement criteria [ Time Frame: Week 12 ]

Secondary Outcome Measures:
  • ACR20 at other time points, ACR50, ACR70, DAS28, EULAR response, tender and swollen joints assessments, physician and patient global assessments, Pain Visual Analog Scale, health outcome assessments [ Time Frame: Up to Week 22 ]

Enrollment: 195
Study Start Date: June 2009
Study Completion Date: February 2011
Primary Completion Date: February 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Arm 1
Part 1: Placebo
Other: Placebo
Part 1: Placebo SC administration every 2 weeks X 10 weeks.
Experimental: Arm 2
Part 1: 100 mg ILV-094 SC Q4W
Drug: ILV-094
Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
Experimental: Arm 3
Part 1: 100 mg ILV-094 SC Q2W
Drug: ILV-094
Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
Placebo Comparator: Arm 4 Other: Placebo
Part 2: Placebo SC administration every 2 weeks X 10 weeks
Experimental: Arm 5
Part 2: 200 mg ILV-094 SC Q2W
Drug: ILV-094
Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Meets the American College of Rheumatology (ACR) 1987 revised criteria for classification of Rheumatoid Arthritis (RA) for at least 6 months prior to screening
  • Active RA at the time of screening and baseline consisting of >= 5 swollen and >= 5 tender joints (28-joint count) and at least 1 of the following at screening: C-reactive protein >= 10 mg/L or Erythrocyte Sedimentation Rate >= 28 mm/h
  • Must be receiving methotrexate for at least 12 weeks, with a stable route and dose (up to 25 mg weekly) for at least 8 weeks prior to the baseline visit.

Exclusion Criteria:

  • Subjects with other rheumatic diseases
  • Cancer or history of cancer (other than cutaneous basal cell carcinoma and squamous cell carcinoma or in situ cervical cancer)
  • Any prior use of B cell-depleting therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00883896

  Hide Study Locations
United States, Arizona
Pfizer Investigational Site
Glendale, Arizona, United States, 85304
United States, California
Pfizer Investigational Site
Palm Desert, California, United States, 92260
United States, Florida
Pfizer Investigational Site
Palm Harbor, Florida, United States, 34684
Pfizer Investigational Site
Sarasota, Florida, United States, 34233
United States, Indiana
Pfizer Investigational Site
Indianapolis, Indiana, United States, 56227
United States, Missouri
Pfizer Investigational Site
St Louis, Missouri, United States, 63117
United States, Ohio
Pfizer Investigational Site
Cincinnati, Ohio, United States, 45219
United States, Pennsylvania
Pfizer Investigational Site
Duncansville, Pennsylvania, United States, 16635
Pfizer Investigational Site
West Reading, Pennsylvania, United States, 19611
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
San Antonio, Texas, United States, 78232
Pfizer Investigational Site
Antwerpen, Belgium, 2170
Pfizer Investigational Site
Brussels, Belgium, 1200
Pfizer Investigational Site
Gent, Belgium, 9000
Pfizer Investigational Site
Hasselt, Belgium, 3500
Pfizer Investigational Site
Liege, Belgium, 4000
Pfizer Investigational Site
Barranquilla, Atlantico, Colombia
Pfizer Investigational Site
Bogota, Cundinamarca, Colombia
Pfizer Investigational Site
Bucaramanga, Santander, Colombia
Pfizer Investigational Site
Rijeka, Croatia, 51000
Pfizer Investigational Site
Zagreb, Croatia, 10000
Pfizer Investigational Site
München, Germany, 80336
Pfizer Investigational Site
Budapest, Hungary, 1023
Pfizer Investigational Site
Budapest, Hungary, 1036
Pfizer Investigational Site
Nyiregyhaza, Hungary, 4400
Pfizer Investigational Site
Szombathely, Hungary, 9700
Pfizer Investigational Site
Yotsukaidou, Chiba, Japan
Pfizer Investigational Site
Maebashi, Gunma, Japan
Pfizer Investigational Site
Sagamihara, Kanagawa, Japan
Pfizer Investigational Site
Kurashiki, Okayama, Japan
Pfizer Investigational Site
Shinjyuku-ku, Tokyo, Japan
Pfizer Investigational Site
Gunma, Japan
Pfizer Investigational Site
Hyogo, Japan
Pfizer Investigational Site
Jalisco, Guadalajara, Mexico, 44690
Pfizer Investigational Site
Amsterdam, Noord-Holland, Netherlands, 1105AZ
Pfizer Investigational Site
Cluj-Napoca, Cluj, Romania, 400275
Pfizer Investigational Site
Bucuresti, Romania, 010584
Pfizer Investigational Site
Bucuresti, Romania, 011172
Pfizer Investigational Site
Bucuresti, Romania, 020125
Pfizer Investigational Site
Bucuresti, Romania, 020983
Pfizer Investigational Site
Targu Mures, Romania, 540136
Russian Federation
Pfizer Investigational Site
Ekaterinburg, Russian Federation, 620102
Pfizer Investigational Site
Moscow, Russian Federation, 115522
Pfizer Investigational Site
Moscow, Russian Federation, 119049
Pfizer Investigational Site
Smolensk, Russian Federation, 214019
Pfizer Investigational Site
St. Petersburg, Russian Federation, 194291
Pfizer Investigational Site
St.Petersburg, Russian Federation, 191015
Pfizer Investigational Site
St.Petersburg, Russian Federation, 194291
Pfizer Investigational Site
Yaroslavl, Russian Federation, 150062
Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Pfizer Identifier: NCT00883896     History of Changes
Other Study ID Numbers: 3199K1-2001
Study First Received: April 17, 2009
Last Updated: November 12, 2012

Keywords provided by Pfizer:
Rheumatoid Arthritis

Additional relevant MeSH terms:
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors processed this record on September 21, 2017